Tyenne(托珠单抗-aazg)已获FDA批准用于治疗多种炎症和免疫疾病,包括类风湿性关节炎、巨细胞动脉炎、多关节型幼年特发性关节炎和全身性幼年特发性关节炎。 Tyenne一种托珠单抗生物仿制药 Tyenne(tocilizumab-aazg)是Actemra(tocilizumab)的生物仿制药,是一种称为白细胞介素6(IL-6)受体拮抗剂的处方药。用于治疗多...
继FDA 批准后,Fresenius Kabi 的 tocilizumab-aazg (Tyenne) 成为第一个具有静脉 (IV) 和皮下制剂的托珠单抗 (Acterma) 生物仿制药。 Tocilizumab-aazg是一种称为白细胞介素 6 (IL-6) 受体拮抗剂的处方药。可阻…
“The FDA’s approval of our tocilizumab biosimilar is a breakthrough in bringing high-quality, affordable, and accessible autoimmune treatment options to patients and health care providers,” Schönhofen states regarding the launch of tocilizumab-aazg. “We are expanding our biosimilars po...
中立来源:动脉网发布时间:2024年07月02日 LAKE ZURICH, Ill.--(BUSINESS WIRE)--Fresenius, via its operating company Fresenius Kabi, announced today the immediate availability in the U.S. of its biosimilar Tyenne® (tocilizumab-aazg), in a subc...查看全文 ...